Zobrazeno 1 - 10
of 92
pro vyhledávání: '"556"'
Autor:
Jeffrey Peppercorn, Aditya Bardia, Anne L Loeser, Mark E. Burkard, Kevin Kalinsky, Hope S. Rugo
Publikováno v:
Journal of Clinical Oncology. 39:1005-1005
1005 Background: Metastatic breast cancer (MBC) is generally incurable and the majority of patients with MBC will remain on treatment indefinitely. Patients usually begin each new treatment at the Recommended Starting Dose (RSD) on the FDA-approved l
Autor:
Vadim S Koshkin, Christine Boyiddle, Naomi Schwartz, Judy Yu, Kristina S. Yu, Ashley Kang, Lisa Bloudek, Qijun Fang, Johanna M. Schafer, Amanda F. Baker, Farzaneh H. Sayedian, Emilie Scherrer
Publikováno v:
Journal of Clinical Oncology. 41:556-556
556 Background: Recent clinical trials suggest an emerging role for HER2-targeted therapy in locally advanced and metastatic UC (LA/mUC). The prevalence of HER2 expression and gene amplification (encoded by ERBB2) in LA/mUC has not been well defined,
Publikováno v:
Journal of Clinical Oncology. 41:790-790
790 Background: Gastrointestinal stromal tumors (GISTs) arise from multiple sites within the gastrointestinal tract. Since the introduction of imatinib in 2002, patients have seen improved overall survival. However, a recent National Cancer Database
Autor:
Anwaar Saeed, Reagan Barnett, Emil Lou, Luciana Madeira da Silva, May Thet Cho, Christopher Hanyoung Lieu, Marwan Fakih, Scott Kopetz, Jonathan M. Loree, Sepideh Gholami
Publikováno v:
Journal of Clinical Oncology. 41:249-249
249 Background: An estimated 85% of CRC are microsatellite stable (MSS) and this population has limited response to immune checkpoint inhibitors (ICIs). Biomarkers are needed to identify responders. Although pembrolizumab received FDA universal appro
Autor:
Vincent J. Picozzi, Teresa Macarulla, Philip A. Philip, Carlos Roberto Becerra, Tomislav Dragovich
Publikováno v:
Journal of Clinical Oncology. 41:TPS770-TPS770
TPS770 Background: Tumor Treating Fields (TTFields) therapy is a loco-regional antimitotic treatment approved for glioblastoma and malignant mesothelioma. TTFields (150 kHz), with/without chemotherapy, induced antiproliferative and anticlonogenic act
Publikováno v:
Journal of Clinical Oncology. 41:556-556
556 Background: To analyze the safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) under the combination treatment with immune checkpoint inhibitors (ICI) in unresectable hepatocellular carcinoma (HCC). Methods: In this retrospect
Autor:
Christopher W. Ryan, Catherine Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell Meng, Ajjai Shivaram Alva, Sumanta K. Pal, Igor Puzanov, Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Nicholas J. Vogelzang, Ian M Thompson, Primo 'Lucky' N. Lara
Publikováno v:
Journal of Clinical Oncology. 40:LBA4500-LBA4500
LBA4500 Background: Patients (pts) who undergo resection of renal cell carcinoma (RCC) with curative intent remain at risk for disease relapse. We conducted a phase III, double-blind, placebo (PB)-controlled, intergroup study to determine the effect
Publikováno v:
Journal of Clinical Oncology. 40:2638-2638
2638 Background: Tumor neoantigens are epitopes derived from tumor-specific mutations that can be incorporated in personalized vaccines to prime T cell responses. DNA vaccines delivered with electroporation have recently shown strong CD8 and CD4 T ce
Autor:
Xiaotian Zhang, Yakun Wang, Shi Xinying, Changsong QI, Zhi Peng, Tong Xie, Dan Liu, Siyuan Cheng, Panpan Zhang, Yiqun Zhang, Qianhui Wan, Nana Hu, Zhihua Pei, Dongliang Wang, Lin Shen
Publikováno v:
Journal of Clinical Oncology. 40:e16085-e16085
e16085 Background: The comprehensive molecular characterization of gastric cancer has been uncovered by The Cancer Genome Atlas (TCGA) research work. However, the genomic feature of Chinese locally advanced or metastatic gastric cancer has been seldo
Publikováno v:
Journal of Clinical Oncology. 40:e13604-e13604
e13604 Background: Virtual tumor board [VTB] platforms are an important aspect of cancer management. They enable easier access to a multidisciplinary team of experts. VTBs are an emerging resource across various cancer care networks in the United Sta